This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Epocrates Feeds Physicians' "App"etites For Consumable Content

Stocks in this article: ATHN

WATERTOWN, Mass., June 19, 2013 (GLOBE NEWSWIRE) -- As the provider of the top medical app for U.S. physicians, Epocrates, Inc., an athenahealth company (Nasdaq:ATHN), serves as the conduit for organizations to deliver succinct and actionable content to clinicians at the point of care. The company has expanded collaborations with three industry-leading organizations— Centers for Disease Control and Prevention (CDC), Agency for Healthcare Research and Quality (AHRQ) and National Comprehensive Cancer Network ® (NCCN®)—to ensure valuable content is getting into the hands of the more than one million healthcare professionals in the Epocrates member network:

  • CDC works with Epocrates to educate physicians on topics such as hepatitis screening for baby boomers, emergency response to blast injuries, immunization updates, emerging resistant bacteria and local disease outbreaks. Epocrates can micro-target alerts to clinicians by region or specialty to ensure that the most relevant content is being received in a digestible mobile format.

CDC has also hand-selected patient education handouts to be hosted on the Epocrates online product for clinicians to conveniently print for or email to patients before leaving the office. Popular patient-friendly handout topics include weight management and sexually transmitted infections.

  • AHRQ provides a way for health professionals to access up-to-date information through the National Guideline Clearinghouse and issues comparative effectiveness reports that provide a basis for sound clinical decisions. Since clinicians are accustomed to relying on Epocrates, it is an organic extension for AHRQ's information to be readily available in the application. To date in 2013, Epocrates has selected more than 35 guidelines to be featured via its targeted DocAlert messaging system, delivering a total of 5,306,920 messages to clinicians' mobile devices. The timely and convenient delivery of these actionable guidelines has helped impact patient treatment in areas such as GERD, drug allergy and cancer screening.

Additionally, the popular AHRQ electronic preventive services selector tool (EPSS) is conveniently accessible within the free Epocrates app.

  • Leveraging its expertise in translating complex or extensive information into a succinct, user-friendly format, Epocrates recently expanded its free app based on the industry-leading NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ® ). Oncologists and hematologists can quickly and intuitively navigate select NCCN Guidelines for prostate, breast and colon cancers, with additional tumor types forthcoming.

Created specifically for mobile devices, the four star-rated iPhone app provides quick access to NCCN Guideline content with minimum steps.

"Epocrates knows how to present information in a digestible format and has made the NCCN Guidelines tremendously easy to use," said Dr. Russell Pachynski of Palo Alto, Calif. "What can I say — they have a secret sauce that works. I know if it comes from Epocrates, it will have all the key info that I need and will be highly relevant to my practice."

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs